Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL148328 | 0.98 | ALDH1A1 (0.53) | PPM1BPTPN1PPP1CCALDH1A1ADRB2 | |
| SCHEMBL8631955 | 0.98 | ALDH1A1 (0.53) | PPM1BPTPN1PPP1CCALDH1A1ADRB2 | |
| SCHEMBL8695709 | 0.96 | PPM1B (0.51) | PPM1BPTPN1PPP1CCALDH1A1ADRB2 | |
| SCHEMBL29104424 | 0.92 | ALDH1A1 (0.61) | PPM1BPTPN1PPP1CCALDH1A1MEN1 | |
| SCHEMBL1245712 | 0.92 | PPM1B (0.45) | PPM1BPTPN1PPP1CCALDH1A1ADRB2 | |
| SCHEMBL526510 | 0.91 | PPM1B (0.55) | PPM1BPTPN1PPP1CCALDH1A1MAPT | |
| SCHEMBL6141464 | 0.91 | — | — | |
| SCHEMBL187699 | 0.88 | ALDH1A1 (0.48) | PPM1BPTPN1PPP1CCALDH1A1ADRB2 | |
| SCHEMBL1246326 | 0.88 | EPHX2 (0.46) | PPM1BPTPN1PPP1CCALDH1A1ADRB2 | |
| SCHEMBL7907216 | 0.88 | EPHX2 (0.46) | PPM1BPTPN1PPP1CCALDH1A1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 318 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018088-A1 | SEPARATION AND PURIFICATION METHOD OF 2-NITROETHANOL | FUDAN UNIVERSITY (CN) | 2024-01-18 | — | — | US | claimed |
| CN-116410093-A | Separation and purification method of 2-nitroethanol | 复旦大学 | 2023-07-11 | — | — | CN | claimed |
| US-5491167-A | INHIBITORS OF CHOLESTEROL BIOSYNTHESIS | SANKYO COMPANY, LIMITED (JP) | 1996-02-13 | — | — | US | claimed |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2024-04-25 | — | — | US | disclosed |
| EP-4025253-B1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR SA (ES) | 2024-03-20 | — | — | EP | disclosed |
| CN-114615999-B | Drug antibody conjugates | 法马马有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20240018088-A1 | SEPARATION AND PURIFICATION METHOD OF 2-NITROETHANOL | FUDAN UNIVERSITY (CN) | 2024-01-18 | — | — | US | disclosed |
| US-20230268178-A1 | PROTECTIVE COMPOSITION AND METHOD OF FORMING PHOTORESIST PATTERN | TAIWAN SEMICONDUCTOR MANUFACTURING CO., LTD. (TW) | 2023-08-24 | — | — | US | disclosed |
| US-20230218774-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2023-07-13 | — | — | US | disclosed |
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-05-18 | — | — | US | disclosed |
| EP-4138923-A1 | DRUG ANTIBODY CONJUGATES | Pharma Mar, S.A. (ES) | 2023-03-01 | — | — | EP | disclosed |
| EP-0437016-A2 | Lipid A analogues having immunoactivating and anti-tumour activity | Sankyo Company Limited (JP) | 1991-07-17 | — | — | EP | disclosed |
| EP-0363223-A2 | 3-Aryloxymethyl-cephalosporin derivatives, their preparation and their medical use | Sankyo Company Limited (JP) | 1990-04-11 | — | — | EP | disclosed |
| EP-0337637-A1 | 2-(Heterocyclylthio)carbapenem derivatives their preparation and their use as antibiotics | Sankyo Company Limited (JP) | 1989-10-18 | — | — | EP | disclosed |
| US-4748172-A | 3-bicyclicpyridinium-methyl cephalosporins | ELI LILLY AND COMPANY (US) | 1988-05-31 | — | — | US | disclosed |
| US-4692443-A | 3-bicyclicpyridinium-methyl cephalosporins | ELI LILLY AND COMPANY (US) | 1987-09-08 | — | — | US | disclosed |
| US-4577014-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1986-03-18 | — | — | US | disclosed |
| EP-0138552-A2 | Improvements on or relating to 3-bicyclicpyridinium-methyl cephalosporins | ELI LILLY AND COMPANY (US) | 1985-04-24 | — | — | EP | disclosed |
| US-4501739-A | BACTERICIDES, ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1985-02-26 | — | — | US | disclosed |
| EP-0074268-A2 | Improvements in or relating to thieno and furopyridinium-substituted cephalosporin derivatives | ELI LILLY AND COMPANY (US) | 1983-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | STT3B, STT3A, TTL | PPM1B 4115/4885PTPN1 1588/4885PPP1CC 4057/4885 |
| US-20240018088-A1 | SEPARATION AND PURIFICATION METHOD OF 2-NITROETHANOL | NUCB2, DNPH1, ECE2 | PPM1B 975/4885PTPN1 3592/4885PPP1CC 1237/4885 |
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | PPM1B 683/4885PTPN1 4536/4885PPP1CC 1531/4885 |
| US-20230218774-A1 | DRUG ANTIBODY CONJUGATES | B3GAT3, MGAT3, SDAD1 | PPM1B 3539/4885PTPN1 925/4885PPP1CC 4494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.